title: Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats.
abstract: This study examined the hypothesis that curcumin supplementation decreases blood levels of IL-6, MCP-1, TNF-alpha, hyperglycemia, and oxidative stress by using a cell-culture model and a diabetic rat model. U937 monocytes were cultured with control (7 mM) and high glucose (35 mM) in the absence or presence of curcumin (0.01-1 microM) at 37 degrees C for 24 h. Diabetes was induced in Sprague-Dawley rats by injection of streptozotocin (STZ) (i.p., 65 mg/kg BW). Control buffer, olive oil, or curcumin (100 mg/kg BW) supplementation was administered by gavage daily for 7 weeks. Blood was collected by heart puncture with light anesthesia. Results show that the effect of high glucose on lipid peroxidation, IL-6, IL-8, MCP-1, and TNF-alpha secretion was inhibited by curcumin in cultured monocytes. In the rat model, diabetes caused a significant increase in blood levels of IL-6, MCP-1, TNF-alpha, glucose, HbA(1), and oxidative stress, which was significantly decreased in curcumin-supplemented rats. Thus, curcumin can decrease markers of vascular inflammation and oxidative stress levels in both a cell-culture model and in the blood of diabetic rats. This suggests that curcumin supplementation can reduce glycemia and the risk of vascular inflammation in diabetes.
authors.affiliation: Department of Pediatrics, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130, USA. sjain@lsuhsc.edu
authors.forename: Sushil K
authors.initials: SK
authors.lastname: Jain
authors.forename: Justin
authors.initials: J
authors.lastname: Rains
authors.forename: Jennifer
authors.initials: J
authors.lastname: Croad
authors.forename: Bryon
authors.initials: B
authors.lastname: Larson
authors.forename: Kimberly
authors.initials: K
authors.lastname: Jones
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D018932:Chemokine CCL2 / Q000097:blood / Q000378:metabolism*; D003474:Curcumin / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000097:blood; D005947:Glucose / Q000494:pharmacology; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism*; D016209:Interleukin-8 / Q000378:metabolism*; D008297:Male; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000378:metabolism*; D020298:U937 Cells
chemical_list: D001786:Blood Glucose; D018932:Chemokine CCL2; D003474:Curcumin; D005947:Glucose; D006442:Glycated Hemoglobin; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha